Advertisement
U.S. markets open in 5 hours 29 minutes
  • S&P Futures

    5,304.75
    -3.50 (-0.07%)
     
  • Dow Futures

    40,104.00
    -40.00 (-0.10%)
     
  • Nasdaq Futures

    18,502.50
    -1.25 (-0.01%)
     
  • Russell 2000 Futures

    2,135.00
    -3.40 (-0.16%)
     
  • Crude Oil

    81.72
    +0.37 (+0.45%)
     
  • Gold

    2,213.90
    +1.20 (+0.05%)
     
  • Silver

    24.61
    -0.14 (-0.57%)
     
  • EUR/USD

    1.0801
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.94
    +0.16 (+1.25%)
     
  • GBP/USD

    1.2612
    -0.0026 (-0.21%)
     
  • USD/JPY

    151.4250
    +0.1790 (+0.12%)
     
  • Bitcoin USD

    70,389.98
    +662.19 (+0.95%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,931.98
    0.00 (0.00%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study

  • Novartis AG (NYSE: NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal muscular atrophy (SMA).

  • The data demonstrated that children with three copies of the SMN2 backup gene who were treated presymptomatically achieved age-appropriate motor milestones, including standing and walking.

  • In addition, a descriptive posthoc analysis of START, STR1VE-EU, and STR1VE-US (n=65) indicated children with SMA Type 1 achieved or maintained necessary measures of bulbar function, including the ability to speak; swallow, and meet nutritional needs; and maintain airway protection.

  • Fourteen patients (93%) walked independently, 11 of whom achieved this milestone within the WHO window of normal development.

  • All patients were independent of nutritional and respiratory support for the study duration.

  • All patients experienced at least one adverse event (AE) after dosing, eight (53%) of which were considered treatment-related. There were no serious, treatment-related AEs.

  • Three patients were reported to have had severe adverse events (SAEs), all of which resolved and were not related to treatment.

  • Price Action: NVS shares are up 2.32% at $84.28 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement